Urovant Sciences Ltd. Banner Image

Urovant Sciences Ltd. has reached its limit for free report views

Work for Urovant Sciences Ltd.? Upgrade Your Profile and unlock all your annual reports.

Urovant Sciences Ltd.

  • Ticker UROV
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Urovant Sciences Ltd. Logo Image
  • 51-200 Employees
  • Based in Irvine, California
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. The Company’s lead product candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist that is being evaluated for overactive bladder (OAB). Urovant Sciences reported positive data from the vibegron 12-week, phase 3 pivotalMore EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study. The Company submitted a New Drug Application to the FDA seeking approval of vibegron for the treatment of patients with OAB in December 2019. Vibegron is also being evaluated for treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH) and for abdominal pain associated with irritable bowel syndrome (IBS). Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases.
4.8 / 5.0 (264)

Urovant Sciences Ltd. reports have an aggregate usefulness score of 4.8 based on 264 reviews.

Urovant Sciences Ltd.

Most Recent Annual Report

Urovant Sciences Ltd.
MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Urovant Sciences Ltd. has reached its limit for free report views.

Older/Archived Annual Reports

Urovant Sciences Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!